Noel Doheny - Epigenomics AG Insider

EPGNF -- USA Stock  

USD 2.68  0.0029  0.11%

  CEO
Mr. Noel Doheny was Chief Executive Officer of Epigenomics Inc. of Epigenomics AG since May 2011. He has 30 years of experience in the field of diagnostics, with over 20 years in senior management. Prior to joining Epigenomics, he held positions as CEO of OpGen, Senior Vice President for the Molecular Diagnostics Division of Affymetrix Inc., Vice President of PreAnalytical Solutions and a member of the Executive Committee at QIAGEN as well as President and CEO of BioStar Inc. He has built several operating teams from the ground up, including the commercial teams to launch novel products at companies such as Ciba Corning, Biostar, and OpGen. Noel obtained degrees in Biology and Chemistry from West Virginia University and attended Georgetown University for postgraduate studies in Biochemistry prior to moving into industry.
  CEO Since 2011      
49 30 243 450  http://www.epigenomics.com

Management Efficiency

The company has return on total asset (ROA) of (44.29) % which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (122.69) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.

Similar Executives

Entity Summary

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics AG is traded on OTC Market in USA.Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Geneststrasse 5 and employs 43 people.

Epigenomics AG Leadership Team

Antje Zeise, Manager Investor Relations
Guenther Reiter, Member of the Supervisory Board
Gregory Hamilton, CEO
Ann Kessler, Member of the Supervisory Board
Heino Prondzynski, Chairman of the Supervisory Board
Helge Lubenow, Member of the Supervisory Board
Thomas Taapken, CEO, CFO and Member of Executive Board
Annett Dietrich, Manager Human Resources
Noel Doheny, CEO of Epigenomics Inc.
Uwe Staub, COO and Member of Executive Board
Albert Weber, Sr. VP of Fin., Accounting and Controlling
Nicola HennebergBusse, Vice President - Business Development
Jorge Garces, President Chief Scientific Officer
Nicholas Potter, Director Reimbursement and Medical Affairs
Peter Vogt, Investor & Public Relations Officer

Stock Performance Indicators

Current Sentiment - EPGNF

Epigenomics AG Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Epigenomics AG. What is your opinion about investing in Epigenomics AG? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Epigenomics AG and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">